Navigation Links
Nabriva Therapeutics Announces Appointment of New CEO
Date:7/2/2008

y available pleuromutilin which is first in class and has significant market potential in multiple indications (eg. SSSI & CAP). All of Nabriva's programs are derived from compounds generated in-house through discovery activity and the company maintains an ongoing effort in medicinal chemistry.

The Company was founded in January 2006 as a spin-out of Sandoz GmbH Kundl. The spin-out was led by Nomura Phase4 Ventures with a Series A financing of EUR42 million with a syndicate that included HBM Partners, GLSV, The Wellcome Trust and Novartis Venture Fund.

Contacts:

Claudia Karner,

Tel: +43(0)1-74093-1240,

e-mail: claudia.karner@nabriva.com


'/>"/>
SOURCE Nabriva Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
2. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
3. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
4. Tobira Therapeutics Inc. Announces Senior Management Team
5. Duska Therapeutics Obtains Standard & Poors Listing
6. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
7. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
8. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
9. Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
10. Barrier Therapeutics to Merge Into Stiefel Laboratories
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PA (PRWEB) January 15, 2014 The Pittcon ... publisher of Food Safety Tech , an e-Journal and ... signed an agreement for the second year for the co-location ... Pittcon 2014. The partnership provides that the registration fee to ...
(Date:1/15/2014)... Look inside the new Preferred Solutions® ... lab, from fluid handling to instruments to supplies. Many ... you order. , Preferred Solutions features a full ... L/S® model for precise flow control and dispensing to ...
(Date:1/15/2014)... and SAN JOSE, California , January ... company developing antibody-drug conjugates for cancer, today announced the appointment ... Directors. Dr Reynolds has over 20 years, development experience gained ... at Seattle Genetics. "I am delighted to welcome ...
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... , ROCKVILLE, Md. , Jan. ... today that it has successfully completed a pre-clinical safety and ...  Results from this study are needed to support an Investigational ... protein particle based RSV (RSV-F) vaccine candidate into clinical development. ...
... ... syndicated radio host Dr. Ken Kronhaus to educate about the need for vascular screening in ... carotid arteries for potential causes of stroke, the abdominal aorta for aneurysms, and the legs ... ...
... new antimalarial drugs after discovering the normal function of ... protein, which causes resistance to the front-line drug chloroquine. ... the malarial chloroquine-resistance factor. The study examined transporter ... cell. The genes for these proteins are present in ...
Cached Biology Technology:NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 2NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 3NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 4NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 5Life Line Screening and Dr. Ken Kronhaus Work Together to Educate People About Vascular Screening 2Life Line Screening and Dr. Ken Kronhaus Work Together to Educate People About Vascular Screening 3Discovery provides new drug targets for malaria cure 2
(Date:4/22/2014)... Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered ... treat most neurodegenerative diseases that are characterized by ... diseases. These molecules are based on what the ... GAIM, which recognizes a characteristic common to many ... misfolded protein. This approach provides NeuroPhage with an ...
(Date:4/22/2014)... developing countries could be monitored from birth to ... a new technique piloted by a London-based university ... be visualised and tracked more quickly, more accurately ... near infra-red spectroscopy (fNIRS), compared to the behavioural ... , Professor Clare Elwell, Professor of Medical ...
(Date:4/21/2014)... HOUSTON, April 21, 2014 Performing brain research that ... advances, University of Houston (UH) junior Khanh (Kate) Nguyen ... science students. A double major in mathematics and physics, ... M. Goldwater Scholarship. , One of the most ... provides funding to sophomore and junior students majoring in ...
Breaking Biology News(10 mins):NeuroPhage discovers GAIM-changing molecules to combat Alzheimer's and related diseases 2NeuroPhage discovers GAIM-changing molecules to combat Alzheimer's and related diseases 3First brain images of African infants enable research into cognitive effects of nutrition 2UH student named Goldwater Scholar, 2 more receive honorable mention 2UH student named Goldwater Scholar, 2 more receive honorable mention 3UH student named Goldwater Scholar, 2 more receive honorable mention 4
... and its consequent lack of access to care appears ... may partly explain the mortality disparity between African-Americans and ... Third AACR Conference on The Science of Cancer Health ... die within four years compared to white patients after ...
... African-American women with breast cancer living in Washington, D.C., ... of insurance type, socioeconomic status and cancer characteristics such ... an associate professor of epidemiology at The George Washington ... the impact of race and socioeconomic status on health ...
... ,Cincinnati, (OH) - The International Rett Syndrome Foundation ... $1.5M in research grants, bringing the 2010 total to ... that moves treatments for Rett syndrome a step closer ... private source of Rett syndrome research funding and with ...
Cached Biology News:Lack of private health insurance impacted cancer survival 2Racial differences in breast cancer treatment persist despite similar economics 2Research becomes a reality for Rett syndrome through new funding 2Research becomes a reality for Rett syndrome through new funding 3Research becomes a reality for Rett syndrome through new funding 4
Animal Origin Free...
IHC Detection Kit (Broad Spectrum AEC)....
...
... Modification Services ,,GenScript offers many ... and antibody fragmentation. Labeling antibodies with ... visualization and quantitation of the target ... preferable to use only the antigen-binding ...
Biology Products: